Novartis Makes $7.8 Billion Bet on the Next Wave of RNA Drugs

Novartis has struck an RNA licensing agreement with China’s Abogen worth up to $7.8 billion, highlighting Big Pharma’s continued race to secure promising new drug technologies.

Novartis is making another major bet on emerging biotechnology.

The pharmaceutical giant has agreed to a licensing deal with China’s Abogen that could be worth approximately $7.8 billion, giving Novartis rights to experimental RNA medicines and access to a broader development platform.

At the centre of the agreement is ABO2203, an experimental therapy developed using Abogen’s RNA technology.

Novartis will receive exclusive rights to the treatment as well as options covering additional medicines developed through the platform.

The enormous headline value does not mean $7.8 billion will immediately change hands. Much of the potential payment depends on future development, regulatory and commercial milestones.

Big Pharma keeps shopping for innovation

For investors, the deal highlights an important pharmaceutical strategy.

Developing drugs internally is expensive, slow and uncertain. Large pharmaceutical companies are increasingly using licensing agreements and acquisitions to bring promising technologies into their pipelines before they reach the market.

RNA technology remains particularly attractive because of its potential applications across multiple diseases.

For Novartis, the agreement adds another potential growth platform without requiring the company to build the technology entirely from scratch.

Whether the deal ultimately justifies its multibillion-dollar price tag will depend on the medicines it produces.

But the scale of the agreement shows how aggressively Big Pharma is competing for the next generation of biotechnology.